Regulatory T-cell therapy in Crohn's disease: challenges and advances

Gut. 2020 May;69(5):942-952. doi: 10.1136/gutjnl-2019-319850. Epub 2020 Jan 24.

Abstract

The prevalence of IBD is rising in the Western world. Despite an increasing repertoire of therapeutic targets, a significant proportion of patients suffer chronic morbidity. Studies in mice and humans have highlighted the critical role of regulatory T cells in immune homeostasis, with defects in number and suppressive function of regulatory T cells seen in patients with Crohn's disease. We review the function of regulatory T cells and the pathways by which they exert immune tolerance in the intestinal mucosa. We explore the principles and challenges of manufacturing a cell therapy, and discuss clinical trial evidence to date for their safety and efficacy in human disease, with particular focus on the development of a regulatory T-cell therapy for Crohn's disease.

Keywords: Crohn's disease; T lymphocytes; immunology; immunoregulation; intestinal T cells.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Cell- and Tissue-Based Therapy / methods*
  • Crohn Disease / diagnosis
  • Crohn Disease / drug therapy*
  • Crohn Disease / immunology*
  • Female
  • Forecasting
  • Humans
  • Intestinal Mucosa / drug effects*
  • Intestinal Mucosa / immunology
  • Intestinal Mucosa / metabolism
  • Male
  • Mice
  • T-Lymphocytes, Regulatory / immunology*
  • Treatment Outcome